BioMed X Institute

🎉 Congratulations, Olivia Amanda Oest Müllertz! 🎉 We are thrilled to celebrate a remarkable achievement by Olivia, a PhD student on our 𝗧𝗠𝗜 team, who has been awarded the 𝗧𝗼𝗽 𝗣𝗼𝘀𝘁𝗲𝗿 𝗔𝘄𝗮𝗿𝗱 at the Controlled Release Society – CRS 2024 Annual Meeting!   🏆 The award recognizes Olivia's outstanding research and her abstract titled: "Intestinal mononuclear phagocytes facilitate macromolecular transport across the intestinal epithelium."   👏 Join us in congratulating Olivia on this incredible accomplishment! We are so proud of her hard work, dedication, and ingenuity. 💡 Let's continue to push boundaries and inspire innovation in delivery science together. Are you interested in career opportunities at the interface between academia and industry? Take a look at the 𝗕𝗶𝗼𝗠𝗲𝗱 𝗫 Institute Career Space: https://bio.mx/career. #CRS2024 #TopPoster #PharmaResearch #InnovativeScience #DeliveryScience #TeamAchievement #TMI

#WelcomeToBioMedX 🌸We are happy to welcome Rakesh HS, our new intern in team VPE – Virtual Patient Engine. 🌸Rakesh is originally from Davanagere, India, where he obtained a bachelor’s degree in Electronics and Communication from Visvesvaraya Technological University. Afterward, he worked for two years at Tech Mahindra. Later, he moved to Heidelberg, Germany, where he is currently pursuing a master’s degree in Applied Data Science and Analytics at SRH University. 🌸Welcome, Rakesh, and good luck! 💡Are you interested in career opportunities at the interface between academia and industry? Take a look at the BioMed X Institute Career Space: https://bio.mx/career.   Douglas McCloskey #VirtualPatientEngine #Bioinformatics #Internship #ComputationalBiology #Career

AI-Driven Drug Development: Safer, But Is It also More Effective?🚀 Recent studies (link in first comment) reveal that #AI-derived drugs have a higher success rate in phase 1 clinical trials compared to historic averages. Yet, efficacy remains a challenge, with no notable improvement in phase 2 and 3 success rates. 📊 What does this mean for the future of drug development? 🔬 Higher safety: AI-discovered molecules have an 80–90% success rate in phase 1 clinical trials, substantially higher than historic industry averages. 📈 Comparable efficacy: In phase 2, the success rate is ∼40%, based on a limited sample size, similar to historic industry averages. 🧩 Room for growth: No significant improvements have been observed in phase 3 success rates, leaving clinical efficacy prediction an open challenge.   Predicting clinical efficacy remains an unsolved puzzle—and that’s where the #VPE Team, led by Douglas McCloskey, is focusing their efforts at BioMed X Institute. 💡 Join us TONIGHT for our webinar in partnership with Code Ocean: AI Agents for Pharma R&D 📅 When: ❗New Date ❗December 17th, 2024 | 12 pm EST / 9 am PT 📍 Where: https://lnkd.in/eXZs5Gtr Let’s collaborate to shape the future of AI in drug development. Share your insights! 💬 #AIinPharma #DrugDevelopment #ClinicalTrials #PharmaRND #ArtificialIntelligence #LifeSciences #DrugDiscovery #HealthTech #Innovation #MedTech #AIResearch

💡From Lab to Hometown: Dr. Stefanie Bärthel shares her research at her hometown during the Heimspiel Wissenschaft! 💡   We’re proud to share that our Team #NST Group Leader, Stefanie Bärthel, was selected to present her research at the Heimspiel Wissenschaft on November 22! 🧬🗣️   Heimspiel Wissenschaft is a joint project by the Hochschulrektorenkonferenz (HRK), the science communication agency con gressa, and the #WisskommLab of the Heidelberg University, with the mission of making science accessible to local communities. 🏡🔬   Returning to her hometown in East Germany, Stefanie captivated the audience with her presentation titled: „Geheime Gespräche im Tumor: Wie Tumor- und Immunzellen miteinander kommunizieren” (Secret conversations inside a tumor: How tumor and immune cells communicate with each other). 🧑🔬🧠   This initiative, funded by the BMBF, brings researchers back to their roots, allowing them to share their groundbreaking work with local communities.   💬 "It was a great experience to share my research on tumor-immune cell communication with my hometown community. Connecting with familiar faces and inspiring curiosity about science was truly rewarding." — Dr. Stefanie Bärthel   A big thank you to everyone who attended and supported this inspiring event! Special thanks to Clara Händeler (con gressa) and David Plessy for their support and organization. 🙌   #HeimspielWissenschaft #BMBF #ScienceCommunication #CancerResearch #Immunology #LocalScience #BioMedX #WisskommLab #Hermsdorf

#WelcomeToBioMedX   🌸We are happy to welcome Sanjana Balaji Kuttae, our new research assistant in team VPE – Virtual Patient Engine. 🌸Sanjana is originally from Chennai, India, where she obtained a bachelor’s degree in bioinformatics from SRM IST Chennai. Then, she moved to Saarbrucken, Germany and earned her master’s degree from Universität des Saarlandes, Saarbrucken. For her master thesis, she collaborated with INM-Leibniz Institute for New Materials, and worked on computational and experimental characterization of optogenetic systems in E. coli. 🌸Welcome, Sanjana, and good luck! Are you interested in career opportunities at the interface between academia and industry? Take a look at the BioMed X Institute Career Space: https://bio.mx/career.   Douglas McCloskey #VirtualPatientEngine #Bioinformatics #ResearchAssistant #ComputationalBiology #Career

🎉 News from Yesterday’s Digital Health Triumphs at EMBL! 🎉 Yesterday, on November 18, 2024, the Digital Health Triumphs event at EMBL brought together leading minds in AI and healthcare. We are proud to share that Douglas McCloskey, Team Lead of the Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates (#VPE), made a significant impact with his presentation. 🌐🧬 The event was a fantastic opportunity for Douglas to engage with top industry experts, exchanging knowledge on the future of digital health and AI in drug discovery. 💬 Key Highlights from Douglas’s Session: 👉Generative AI for biomedical diagnostic applications from image modalities (e.g., CT scans) has become state of the art as a result of implementing smart adaptations to existing image and video generative AI technologies. 👉However, limiting access to patient data has and continues to hamper its clinical impact where generalization and accuracy are paramount. 👉AI Agentic workflows could make biomedical diagnostic applications from image modalities more accessible by providing a easy to use natural language interface to clinicians for a technology that requires strong domain expertise to use. Thank you to everyone who attended and supported this incredible event! 🙌 For more details, visit: Digital Health Triumphs - EMBL: https://lnkd.in/epd33Ysg Douglas McCloskey | Daniela Beyer | Alyssa V. Are you interested in how AI agents can revolutionize Pharma R&D by seamlessly communicating with PK/PD/QSP models and Biomedical Knowledge Graphs? 📊🤖 Don’t miss our upcoming webinar in collaboration with: Code Ocean: AI Agents for Pharma R&D 📅 Date: November, 26, 2024 ⏰ Time: 6 pm Berlin / 12 pm EST / 9 am PT Register Now: AI Agents for Pharma R&D https://lnkd.in/eXZs5Gtr #BioMedX #DigitalHealthTriumphs #VirtualPatients #ClinicalTranslation #DrugDiscovery #EMBL2024 #AIinHealthcare #SanofiCollaboration

🚀 Exciting Highlights from the AI Driven Drug Discovery Summit! 🚀 Our #VPE Team Lead, Douglas McCloskey, represented BioMed X Institute with inspiring insights at the AI Driven Drug Discovery Summit in Boston from November 12-14! 🌐✨ He shared the latest advancements from his #VPE Team, which, in partnership with Sanofi, is pioneering research on the Next Generation Virtual Patient Engine to accelerate the clinical translation of drug candidates. He also engaged with top industry leaders on the future of AI-driven drug discovery, fostering insightful discussions on its transformative potential. Douglas also joined QIAGEN’s pre-day Knowledge Graph Insight Session, diving into the powerful role of knowledge graphs in modern biopharma research. 📊🤖 Here’s a quick recap of the summit highlights: 👉 Virtual patients (sometimes referred to as DigitalTwins) have the potential to reduce #DrugDiscovery and #DrugDevelopment in the #Pharmaceutical industry time and cost while improving access to life changing treatments to underrepresented patient populations. 👉 High quality (curated) biomedical #KnowledgeGraphs (such as the QIAGEN BKB-HD) are critical enablers to build virtual patients using knowledge-driven or data-driven in silico science. 👉 #AI enabled agentic workflows can expedite manual tasks related to building knowledge graphs and can democratize access to virtual patient technologies. See results (link in the first comment) from our most recent #Hackathon (VPE) "Results for AI agents for life sciences". Thank you to everyone who connected with us at the summit! We’re thrilled to bring back valuable insights and continue driving innovation in clinical translation and drug development. 🙌💡 Douglas McCloskey | Kyle Nilson, PhD | Ted Johnson | Scott J Magin | SHU YAN | Venkatesh Moktali, PhD | Are you interested in how AI agents can revolutionize Pharma R&D by seamlessly communicating with PK/PD/QSP models and Biomedical Knowledge Graphs? 📊🤖 Don’t miss our upcoming webinar in collaboration with Code Ocean: AI Agents for Pharma R&D 📅 Date: November, 26, 2024 ⏰ Time: 6 pm Berlin / 12 pm EST / 9 am PT Register Now: AI Agents for Pharma R&D https://lnkd.in/eXZs5Gtr #BioMedX #AIDrugDiscovery #VirtualPatients #ClinicalTranslation #KnowledgeGraph #Biopharma #InnovationInBiotech #FutureOfMedicine #AIDDD

🎉 Exciting Updates from BioMed X Institute at the Sony Biotechnology Europe Spectral Cytometry Event 2024 at #VIB in Ghent! 🎉   We’re thrilled to announce that our talented scientists, Dr. Lyn Lim and Adrián Parrilla Mesas, were invited to present their cutting-edge research at the Sony Users Meeting on November 14th. 🌐🧬   Dr. Lyn Lim delivered an insightful talk on:  "Diversity and granularity in immunometabolism: Combining SCENITH with spectral flow". She shared her expertise on how spectral flow cytometry can provide a deeper understanding of the immune system's metabolic landscape, opening doors to novel therapeutic strategies. 🌟A key highlight of her presentation was a novel technique projecting metabolic measurements to single-cell resolution 🔬    Adrián Parrilla Mesas showcased his innovative work through a poster presentation titled: “Limit of Detection for Extracellular Vesicle Analysis Using ID7000”. His research focuses on pushing the boundaries of extracellular vesicle detection to enhance diagnostic capabilities 🖼️🧑🔬 🌟 He spotlights the common fallacy of using beads for size estimation of vesicles and proposes a better solution 🎯   This event, hosted at the VIB-CENTER for inflammation, brought together experts in spectral flow cytometry to explore the latest advancements in the field. It was an incredible opportunity for our team to connect, share, and learn from fellow researchers 🙌✨   A big thank you to everyone who attended and supported our scientists! 🚀🔍   Gorjana Rackov #BioMedX #TeamTDA #SpectralFlowCytometry #ImmunoMetabolism #ExtracellularVesicles #ScientificResearch #FlowCytometry #Ghent2024 #SonyUsersMeeting #BiotechInnovation

Did you get a chance to hear about the 3rd Precision Psychiatry Research Symposium (PPRS) held Boehringer Ingelheim in Biberach, our research site in Germany? It was truly delightful to be a part of this excellently organized conference, all thanks to our CNS colleagues, especially Lothar Kussmaul and his team (Thaíse Denz, Dr. Hsing-Jung Chen-Engerer, Enise Ergin, Oana Dormann, Marzieh Funk, Tudor Ionescu, Patrick Latuske and Marion Ponserre). The event was graced by top-tier speakers, engaging discussions, and an outstanding poster session yesterday evening. Observing my company devote such energy to forge connections with the world's leading researchers is a unique and powerful commitment. It was heartening to see the Open Science Group highlighted in the 5 posters and scientific contributions from our initiatives like #opnMe, BioMed X Institute projects, and PPPs projects under the umbrella of Innovative Health Initiative (IHI). A special thanks to Hugh Marston for his relentless efforts in the pursuit of discovering new drugs for Mental Health disorders. Thank you to our dear collaborators and colleagues working on our projects showcased at the PPRS: Christian Tidona, Khulan Sergelen, Ebru Ercan Herbst, Emre Kul, Judith Schweimer, Lorenza Magno, Dr. Hsing-Jung Chen-Engerer, Martin Graf, George Augustine, Heike Schauerte, Katrin Eschmann

#WelcomeToBioMedX   💐We are happy to welcome Galia Magela Montalvo Bereau, our new postdoc in team #NST – New Strategies to Engage Neutrophils in Solid Tumors. 💐Galia is a dedicated, curious, and enthusiastic biological scientist. Originally from #Cuba, she completed her bachelor’s in #Biochemistry and master’s in #Immunology at the University of Havana. 💐Her research journey began at the Center of Molecular Immunology in Havana, where she worked in the Immune Regulation Department as a #researcher, focusing on #Interleukin-2 and rationally designed mutants to modulate the immune system for improved cancer treatments. 💐With a Swiss government excellence scholarship, she spent over a year optimizing T-cell expansion and differentiation conditions for cell transfer therapies as part of the T-cell engineering group at the Ludwig Cancer Research in #Lausanne, Switzerland. 💐During her #PhD, she focused on enhancing T-cell search efficiency by targeting cytoskeletal components with tailored drugs. This was a joint project between the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), the Universitätsklinikum des Saarlandes, and the Experimental Physics Department at the Universität des Saarlandes. 💐Welcome, Galia, and good luck! Are you interested in #career opportunities at the interface between #academia and #industry? Take a look at the BioMed X Institute Career Space: https://bio.mx/career. Stefanie Bärthel